Figure 3.
Anticancer therapeutic potential of Mogamulizumab (KW-0761). Mogamulizumab is shown in Figure 4. The antibody is prepared by glycoengineering and is defucosylated, enhancing the ADCC response promoted by cytotoxic T and NK cells. Elimination of CCR4+ Treg cells further enhances the immune response of cytotoxic T cells against the tumor cells.